Clinical trials: Early Triple-Negative Breast Cancer
Breast Cancer, Early-Onset
CIPHER Study: Pilot Study to Study the Role of ctDNA in Triple Negative and HER2 Positive Early Stage
Primary Objective: 1) To examine the impact of Circulating tumor DNA (ctDNA) (expressed as mean tumor molecules per ml) on treatment decision making in patients with early stage breast cancer after neoadjuvant therapy and surgery…
- Trial name
- NCT05333874
- Testing
- Neoadjuvant chemotherapy administered before surgical extraction of a tumor, Observational
- Where
- 12 sites in United States
- Volunteers
- 34 people
- Sponsor
- Rutgers, The State University of New Jersey
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8
Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer
This phase I trial tests the safety, side effects, and best dose of a personalized vaccine (tumor membrane vesicle or TMV vaccine) by itself and in combination with checkpoint inhibitor (pembrolizumab or ipilimumab) in treating…
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
- Trial name
- NCT06324240
- Testing
- Ipilimumab, Pembrolizumab, Vaccine Therapy
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- Emory University
TNBC, Triple Negative Breast Cancer, Early Breast Cancer
MRI-Guided Neoadjuvant Treatment De-Escalation in Stage II-III TNBC
Breast cancer is the most common malignancy among women worldwide. Triple-negative breast cancer (TNBC), defined by the lack of estrogen receptor, progesterone receptor, and HER2 expression, comprises approximately 15% of all…
- Trial name
- NOGA (NCT07327021)
- Testing
- Treatment De-Escalation and Early Surgery
- Where
- 2 sites in Israel
- Volunteers
- 54 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer.
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8
- Trial name
- NCT05929768
- Testing
- Biospecimen Collection, Carboplatin, Cyclophosphamide
- Where
- 963 sites in United States, Mexico and 1 more
- Volunteers
- 2,400 people
- Sponsor
- SWOG Cancer Research Network
Triple Negative Breast Cancer (TNBC), HER2-Positive Breast Cancer
Home-Based Exercise Program During Neoadjuvant Treatment to Improve Fatigue and Quality of Life in Early HER2-Positive and Triple-Negative Breast Cancer Patients
The goal of this trial is to learn if a home-based exercise program (intervention) reduces fatigue and improves quality of life in adult patients with early breast cancer who are proposed for preoperative chemotherapy.
- Conditions
- Triple Negative Breast Cancer (TNBC), HER2-Positive Breast Cancer, Early Breast Cancer, Cancer-related Fatigue
- Trial name
- HoPEx-Breast (NCT06782698)
- Testing
- Home-based exercise program, Promotion of Healthy Physical Activity
- Where
- Portugal
- Volunteers
- 50 people
- Sponsor
- Centro Hospitalar Universitário de Santo António
Cancer, Breast, Triple Negative Breast Cancer
VISION: Triple Negative Breast Cancer Sample and Clinical Data Acquisition Study
Background: Despite improvements in the treatment of Triple Negative Breast Cancer (TNBC), the cancer returns in half of the women and shockingly 40% are dead within 5 years of their initial cancer diagnosis.
- Conditions
- Cancer, Breast, Triple Negative Breast Cancer, Early-stage Breast Cancer
- Trial name
- NCT06409221
- Testing
- Non-interventional study, Observational only
- Where
- United Kingdom
- Volunteers
- 200 people
- Sponsor
- Concr
Early Breast Cancer, Neoadjuvant Therapy
QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk TNBC Breast Cancer
This study will look at the efficacy and safety of QL1706 plus albumin-bound paclitaxel and carboplatin in a neoadjuvant setting, in high-risk, TNBC early breast cancer.
- Conditions
- Early Breast Cancer, Neoadjuvant Therapy, TNBC, Triple Negative Breast Cancer
- Trial name
- QUEEN-Dream (NCT06404736)
- Testing
- Bispecific antibody (bsAb) targeting PD-1 and CLTA-4, Albumin-bound paclitaxel, Carboplatin
- Where
- China
- Volunteers
- 73 people
- Sponsor
- Fudan University
Early Breast Cancer, Triple Negative Breast Cancer
Trial for Treatment of High Risk BC With Two Sequences of Neoadjuvant Chemotherapy With Pembrolizumab
Phase II, randomized, Active-controlled open label trial for treatment of high risk, HR-/HER2- (triple negative) breast cancer, with two sequences of neoadjuvant chemotherapy on a background of pembrolizumab
- Trial name
- KEYPARTNER (NCT06371807)
- Testing
- Pembrolizumab injection
- Where
- 3 sites in Portugal
- Volunteers
- 20 people
- Sponsor
- Fundacao Champalimaud
Triple Negative Breast Cancer, Early-stage Breast Cancer
Evaluating the Efficacy of Neratinib on Live Cell HER2 Signaling Transduction Analysis Positive Triple Negative Breast
An Open-Label Phase II Trial to Evaluate the Efficacy and Safety of Neoadjuvant Neratinib Followed by Weekly Paclitaxel and Carboplatin Plus Neratinib in Early Stage Triple-Negative Breast Cancer Patients Who Exhibit Enhanced…
- Conditions
- Triple Negative Breast Cancer, Early-stage Breast Cancer, HER2-positive Breast Cancer
- Trial name
- FACT-2 (NCT03812393)
- Testing
- Neratinib
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- West Cancer Center
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8
Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer
This phase I trial studies how well chemokine modulation therapy and standard chemotherapy given before surgery work in treating patients with early stage triple negative breast cancer.
- Conditions
- Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8
- Trial name
- NCT04081389
- Testing
- Celecoxib, Cyclophosphamide, Doxorubicin
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Roswell Park Cancer Institute
Triple Negative Breast Cancer, Breast Cancer Stage II
Implantable Microdevice for TNBC - Pilot Study
The goal of this research study is to evaluate the safety and feasibility of implanting and retrieving a microdevice that releases microdoses of a specific drug or combination of drugs as a possible tool to evaluate the…
- Conditions
- Triple Negative Breast Cancer, Breast Cancer Stage II, Breast Cancer Stage III, Breast Cancer
- Trial name
- NCT05774886
- Testing
- Implantable Microdevice (IMD)
- Sponsor
- Dana-Farber Cancer Institute
Early Triple Negative Breast Cancer
BRCA1-associated DNA Repair Dysfunction in Patients With Early Triple Negative Breast Cancer Treated With Neoadjuvant Platinum-based Chemotherapy
The purpose of this study is to assess efficacy of platinum-based neoadjuvant chemotherapy in correlation with BRCA1-associated DNA repair dysfunction in patients with early triple negative breast cancer.
- Trial name
- NCT01672671
- Testing
- Doxorubicin, Paclitaxel, Cisplatin
- Where
- Russia
- Volunteers
- 41 people
- Sponsor
- Russian Academy of Medical Sciences